share_log

Illumina | 8-K: Current report

Illumina | 8-K: Current report

Illumina | 8-K:重大事件
SEC announcement ·  04/09 16:20
Moomoo AI 已提取核心訊息
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, has announced significant changes to its executive management team. Joydeep Goswami, who has been with the company since 2019, will be leaving his roles as Chief Financial Officer and Chief Strategy and Development Officer. Ankur Dhingra will take over as the new CFO starting April 15, 2024, bringing extensive experience from his previous roles at Summit Therapeutics Inc., CareDx, and Agilent Technologies. Dhingra's appointment comes with a comprehensive compensation package, including a base salary, variable compensation, equity awards, and additional benefits. Jakob Wedel has been appointed as Chief Strategy and Corporate Development Officer, a role previously held by Goswami. Wedel, who joined Illumina in November 2023, has a strong background in...Show More
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, has announced significant changes to its executive management team. Joydeep Goswami, who has been with the company since 2019, will be leaving his roles as Chief Financial Officer and Chief Strategy and Development Officer. Ankur Dhingra will take over as the new CFO starting April 15, 2024, bringing extensive experience from his previous roles at Summit Therapeutics Inc., CareDx, and Agilent Technologies. Dhingra's appointment comes with a comprehensive compensation package, including a base salary, variable compensation, equity awards, and additional benefits. Jakob Wedel has been appointed as Chief Strategy and Corporate Development Officer, a role previously held by Goswami. Wedel, who joined Illumina in November 2023, has a strong background in strategy, having worked with global consulting firms and co-founding a strategy firm. Goswami will remain in an advisory capacity until June 30 to assist with the transition. Illumina also reaffirmed its financial guidance for Q1 2024 and the full year, as previously announced in February 2024. The company's leadership changes and financial outlook were disclosed in a press release on April 9, 2024.
DNA測序和基於陣列的技術領域的全球領導者Illumina, Inc. 宣佈對其執行管理團隊進行重大調整。自2019年以來一直在公司工作的喬伊迪普·戈斯瓦米將辭去首席財務官兼首席戰略與發展官的職務。安庫爾·丁格拉將從2024年4月15日起接任新任首席財務官,他將帶來他之前在Summit Therapeutics Inc.、CaredX和安捷倫科技公司任職的豐富經驗。丁格拉的任命附帶全面的薪酬待遇,包括基本工資、可變薪酬、股權獎勵和其他福利。雅各布·韋德爾被任命爲首席戰略和企業發展官,此前該職位由戈斯瓦米擔任。韋德爾於2023年11月加入Illumina,具有深厚的戰略背景,曾在全球諮詢公司工作並共同創立了一家戰略公司。戈斯瓦米將在6月30日之前繼續擔任顧問職務,以協助過渡。Illumina還重申了先前在2024年2月公佈的2024年第一季度及全年財務指導。該公司的領導層變動和財務前景已在2024年4月9日的新聞稿中披露。
DNA測序和基於陣列的技術領域的全球領導者Illumina, Inc. 宣佈對其執行管理團隊進行重大調整。自2019年以來一直在公司工作的喬伊迪普·戈斯瓦米將辭去首席財務官兼首席戰略與發展官的職務。安庫爾·丁格拉將從2024年4月15日起接任新任首席財務官,他將帶來他之前在Summit Therapeutics Inc.、CaredX和安捷倫科技公司任職的豐富經驗。丁格拉的任命附帶全面的薪酬待遇,包括基本工資、可變薪酬、股權獎勵和其他福利。雅各布·韋德爾被任命爲首席戰略和企業發展官,此前該職位由戈斯瓦米擔任。韋德爾於2023年11月加入Illumina,具有深厚的戰略背景,曾在全球諮詢公司工作並共同創立了一家戰略公司。戈斯瓦米將在6月30日之前繼續擔任顧問職務,以協助過渡。Illumina還重申了先前在2024年2月公佈的2024年第一季度及全年財務指導。該公司的領導層變動和財務前景已在2024年4月9日的新聞稿中披露。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息